CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the incidence of B7 homolog 3 protein (B7-H3) expression in different solid tumors, and develop an understanding of its role in cancer proliferation, metastasis and treatment resistance.
  • Recollect available efficacy and safety findings with B7-H3-directed antibody-drug conjugates for patients with lung cancer, and assess the future role these agents might play in treatment.
  • Describe the scientific rationale for the use of tumor treating fields (TTFields) in the treatment of non-small cell lung cancer (NSCLC), and appraise published efficacy and safety data with TTFields in combination with chemotherapy or immunotherapy for patients with recurrent metastatic disease.
  • Consider available research documenting the safety and efficacy of TTFields in the treatment of brain metastases from NSCLC, and discern how this information might be applied to future patient care.
  • Recognize the biological rationale for the development of DLL3 x CD3-directed bispecific T-cell engager therapy for patients with small cell lung cancer (SCLC), and consider the current role of this therapeutic strategy for relapsed/refractory disease.
  • Recall ongoing trials evaluating the potential role of novel therapeutic approaches for progressive NSCLC and SCLC, and appropriately counsel patients regarding enrollment.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
  
  Audio Program: ResearchToPractice.com/OncologyToday24/NovelLung and evaluation ResearchToPractice.com/OncologyToday24/NovelLung/CME.
  
  Video Program: ResearchToPractice.com/OncologyToday24/NovelLung/Video and evaluation ResearchToPractice.com/OncologyToday24/NovelLung/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Melissa Johnson, MD
  Director, Lung Cancer Research Program
  Sarah Cannon Research Institute
  Associate Director of Drug Development for the Drug Development Unit in Nashville
  SCRI Oncology Partners
  Nashville, Tennessee
  
  Consulting Agreements: AbbVie Inc, Alentis Therapeutics AG, Amgen Inc, Arcus Biosciences, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Biohaven, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, D3 Bio, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Gritstone bio, GSK, Hookipa Pharma Inc, Immunocore, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Mirati Therapeutics Inc, ModeX Therapeutics, Molecular Axiom, Normunity, Novartis, Novocure Inc, Pfizer Inc, Pyramid Biosciences, Revolution Medicines, Sanofi, Seagen Inc, Synthekine, Takeda Pharmaceuticals USA Inc, Zai Lab; Contracted Research: AbbVie Inc, Adaptimmune, Amgen Inc, Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, ArriVent Biopharma, Artios Pharma Limited, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BerGenBio ASA, BioAtla, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics Inc, Centessa Pharmaceuticals, Conjupro Biotherapeutics, Corvus Pharmaceuticals, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dracen Pharmaceuticals, Elicio Therapeutics, EMD Serono Inc, EQRx, Erasca, Exelixis Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Genocea, Gritstone bio, GSK, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences Inc, Immuneering Corporation, Immunitas Therapeutics, Immunocore, Impact Therapeutics, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Kartos Therapeutics, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merus, Mirati Therapeutics Inc, Mythic Therapeutics, NeoImmuneTech, Neovia Oncology, NextPoint Therapeutics, Novartis, Numab Therapeutics AG, Nuvalent, OncoC4, Palleon Pharmaceuticals, Pfizer Inc, PMV Pharma, Rain Oncology, Rascal Therapeutics, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Roche Laboratories Inc, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals Inc, Shattuck Labs, SiliconTherapeutics, Summit Therapeutics, Syndax Pharmaceuticals, SystImmune Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TCR^²Therapeutics, Tempest Therapeutics, TheRas, Tizona Therapeutics Inc, Turning Point Therapeutics Inc, Vividion Therapeutics, Vyriad, Y-mAbs Therapeutics Inc; Nonrelevant Financial Relationships: City of Hope National Medical Center, Memorial Sloan Kettering Cancer Center.
  
  Ticiana Leal, MD
  Associate Professor
  Department of Hematology and Oncology
  Director, Thoracic Oncology
  Winship Cancer Institute
  Emory University
  Atlanta, Georgia
  
  Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Boehringer Ingelheim Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, Gilead Sciences Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Novartis, Novocure Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Advaxis Inc, Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, Pfizer Inc, Synthekine; Data and Safety Monitoring Board/Committee: OncoC4; Travel Support: Regeneron Pharmaceuticals Inc, Sanofi.
  
  Manish Patel, MD
  Director of Drug Development
  Florida Cancer Specialists & Research Institute
  Associate Director of Drug Development
  Sarah Cannon Research Institute
  Sarasota, Florida
  
  Consulting Agreements: Accutar Biotechology Inc, Daiichi Sankyo Inc, Kura Oncology, Nurix Therapeutics Inc, Olema Oncology, UCB Japan; Honorarium: Janssen Biotech Inc; Leadership: iON Pharma USA; Research Funding to Institution: Accutar Biotechnology Inc, Acerta Pharma — A member of the AstraZeneca Group, Adagene, ADC Therapeutics, Agenus Inc, Allorion Therapeutics, Amgen Inc, Artios Pharma Limited, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, BioTheryX Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Compugen, Conjupro Biotherapeutics, Cullinan Therapeutics, Cyteir Therapeutics, Daiichi Sankyo Inc, Elevar Therapeutics, Erasca, Genentech, a member of the Roche Group, Georgiamune, Gilead Sciences Inc, GSK, H3 Biomedicine, Hengrui Therapeutics Inc, HotSpot Therapeutics, Hutchison MediPharma, Immune-Onc Therapeutics Inc, Immunitas Therapeutics, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Kineta, KLUS Pharma, Kura Oncology, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Merck, Moderna, Novartis, Nurix Therapeutics Inc, Olema Oncology, ORIC Pharmaceuticals, Pfizer Inc, Pionyr Immunotherapeutics, Prelude Therapeutics, PureTech Health, Ribon Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals Inc, Step Pharma, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, a GSK Company, Transcenta, Treadwell Therapeutics, Vividion Therapeutics, Zymeworks Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Daiichi Sankyo Inc and Novocure Inc.
  
  Release date: August 2024
  Expiration date: August 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.